Blocking NS3-NS4B interaction inhibits dengue virus in non-human primates.

ABSTRACT: Dengue is a major health threat and the number of symptomatic infections caused by the four dengue serotypes is estimated to be 96 million¹ with annually around 10,000 deaths². However, no antiviral drugs are available for the treatment or prophylaxis of dengue. We recently described the interaction between non-structural proteins NS3 and NS4B as a promising target for the development of pan-serotype dengue virus (DENV) inhibitors³. Here we present JNJ-1802-a highly potent DENV inhibitor that blocks the NS3-NS4B interaction within the viral replication complex. JNJ-1802 exerts picomolar to low nanomolar in vitro antiviral activity, a high barrier to resistance and potent in vivo efficacy in mice against infection with any of the four DENV serotypes. Finally

SUBMITTER: Goethals O 

PROVIDER: S-EPMC10033419 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature